A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Latest Information Update: 31 Mar 2015
At a glance
- Drugs VB 201 (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 17 Feb 2015 According to a media release, VB-201 in patients with psoriasis did not meet its primary endpoint; VBL Therapeutics does not plan to continue development of VB-201 in this indication.
- 17 Feb 2015 Primary endpoint of 'PASI 50 week 16 and week 24' has not been met, according to a VBL Therapeutics media release.
- 17 Feb 2015 Top-line results published in a VBL Therapeutics media release.